Product News and Recalls

FDA to study misleading ads such as the 2007-2008 Yaz commercials

The federal Food and Drug Administration will study the impact of “corrective” advertising on consumers’ false perceptions of drug safety and effectiveness.

In a notice posted to the Feb. 29 Federal Register, the agency cited ads run by Bayer in 2009 at FDA’s behest to correct false or misleading claims and omissions it had made when advertising Yaz.

But the agency said: “researchers and policymakers currently lack exhaustive empirical literature regarding the various impacts of corrective (direct-to-consumer) advertisements on prescription drug consumers. The current project will examine how variations in corrective advertising may impact consumers’ misleading product beliefs.”

Researchers will examine three factors: message exposure, similarity of original and corrective ads, and length of time between exposure to original and corrective ads in a “medium-prevalence” medical condition, or one affecting 5-to-10 percent of the U.S. adult population.

The study will be conducted online. The agency will have to wait for a 60-day public comment period, which ends April 30, to close before getting started.

For more information and to submit comments, go here:

A number of studies have shown that Yaz, Yasmin, Beyaz, Ocella, and other drospirenone-containing birth control pills are more likely to cause blood clots, pulmonary embolism, and stroke than other birth control drugs.

Women who have suffered injury as a result of taking those pills have legal remedies available. If you or someone you love developed a blood clot, stroke, or pulmonary embolism while taking Yaz, Yasmin, Beyaz, or Ocella, you may be eligible to recover damages. Please contact Lopez McHugh for a free consultation. Call today because if you wait too long, you may be barred from recovering for your injuries by your state’s time limits.